Eosinophilic Granulomatosis with Polyangiitis

• FDA approval · 2020-09-25
  FDA Approved: NUCALA — Supplemental Application (GlaxoSmithKline LLC)

  FDA approves a supplemental application for NUCALA (mepolizumab) submitted by GlaxoSmithKline LLC.

• FDA approval · 2019-10-03
  FDA Approved: FASENRA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

  FDA approved a supplemental application for FASENRA (benralizumab) from AstraZeneca, updating its labeling and/or indications.

• FDA approval · 2019-09-12
  FDA Approved: NUCALA — Supplemental Application (GlaxoSmithKline LLC)

  The FDA approved a supplemental application for NUCALA (mepolizumab) submitted by GlaxoSmithKline LLC.